Key Takeaways
- • Adenia Partners closes Entrepreneurial Fund I at $180 million hard cap, exceeding its original $150 million target in less than a year, signaling strong institutional confidence in Africa-focused small and lower mid-cap control investments.
- • SPE Capital-led consortium completes Orchidia Pharmaceutical investment in Egypt, with participation from EBRD, Proparco, and the Belgian Investment Company for Developing Countries, targeting the continent's pharmaceutical manufacturing sector.
- • Phatisa exits majority stake in Zambia's Goldenlay to Vanden Avenne Group, marking a transition in ownership of the country's largest table-egg producer; AgDevCo simultaneously exits its long-term debt position in the transaction.
- • Three transactions across Egypt, Zambia, and broader African markets demonstrate sustained private capital deployment in pharma, agribusiness, and lower mid-cap segments despite moderating deal volumes across the continent.
Summary
African private capital markets recorded three significant transactions in May 2026, reflecting continued investor interest in the continent's undercapitalized business segments despite broader market headwinds. The activity underscores a strategic shift toward control investments and infrastructure-heavy sectors where institutional capital addresses persistent gaps in African entrepreneurial finance.
Adenia Partners achieved a notable fundraising milestone by closing its Adenia Entrepreneurial Fund I at a $180 million hard cap, surpassing its initial $150 million target within less than a year of launch. The fund's focus on control investments in small and lower mid-cap companies positions it to address what the firm identifies as the largest and most undercapitalized segment of the continent's private sector—a market niche that has historically attracted limited institutional attention.
In Egypt's pharmaceutical sector, a SPE Capital-led consortium completed an investment in Orchidia Pharmaceutical Industries, a manufacturer specializing in eye-care medicines. The transaction included co-investment from the European Bank for Reconstruction and Development, Proparco (the French development finance institution), and the Belgian Investment Company for Developing Countries. This multilateral structure reflects growing institutional confidence in African healthcare manufacturing and demonstrates how blended finance mechanisms continue to de-risk private capital deployment across the continent.
Zambia's agribusiness sector saw significant ownership transition as Phatisa sold its majority stake in Goldenlay, the country's largest table-egg producer, to Belgium-based Vanden Avenne Group, an integrated feed and protein manufacturer. AgDevCo, which had provided long-term debt financing to Goldenlay, simultaneously exited its position. The fully integrated producer, which operates large-scale production, upstream feed farming, and nationwide distribution serving retail, informal trade, and regional exports, represents the type of operationally mature business increasingly attractive to strategic acquirers seeking exposure to African agricultural value chains.
Together, these three transactions illustrate institutional capital's continued focus on operational control, sector diversification beyond traditional extractives, and reliance on development finance partners to structure investments across the continent's emerging markets.
Adenia Partners achieved a notable fundraising milestone by closing its Adenia Entrepreneurial Fund I at a $180 million hard cap, surpassing its initial $150 million target within less than a year of launch. The fund's focus on control investments in small and lower mid-cap companies positions it to address what the firm identifies as the largest and most undercapitalized segment of the continent's private sector—a market niche that has historically attracted limited institutional attention.
In Egypt's pharmaceutical sector, a SPE Capital-led consortium completed an investment in Orchidia Pharmaceutical Industries, a manufacturer specializing in eye-care medicines. The transaction included co-investment from the European Bank for Reconstruction and Development, Proparco (the French development finance institution), and the Belgian Investment Company for Developing Countries. This multilateral structure reflects growing institutional confidence in African healthcare manufacturing and demonstrates how blended finance mechanisms continue to de-risk private capital deployment across the continent.
Zambia's agribusiness sector saw significant ownership transition as Phatisa sold its majority stake in Goldenlay, the country's largest table-egg producer, to Belgium-based Vanden Avenne Group, an integrated feed and protein manufacturer. AgDevCo, which had provided long-term debt financing to Goldenlay, simultaneously exited its position. The fully integrated producer, which operates large-scale production, upstream feed farming, and nationwide distribution serving retail, informal trade, and regional exports, represents the type of operationally mature business increasingly attractive to strategic acquirers seeking exposure to African agricultural value chains.
Together, these three transactions illustrate institutional capital's continued focus on operational control, sector diversification beyond traditional extractives, and reliance on development finance partners to structure investments across the continent's emerging markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.